
The global pharmaceutical industry continues to experience strong growth driven by innovation in biologics, oncology, diabetes and obesity treatment, vaccines, and rare disease therapies. In August 2026, Pharm Exec magazine published the 2026 Pharm Exec 50, ranking the Top 50 pharmaceutical companies worldwide by prescription drug (Rx) sales in fiscal year 2025.
This ranking is widely regarded as one of the most authoritative industry benchmarks, offering valuable insight for pharmaceutical manufacturers, API and packaging suppliers, pharmaceutical equipment companies, and distributors and contract manufacturing organizations (CMOs).
Below is the fully updated 2026 Global Top 50 Pharmaceutical Companies List, based on 2025 Rx sales.
目次
トグルこのランキングは以下を反映しています 実際の商業パフォーマンス, not market capitalization or valuation. Figures in the table are 2025 Rx sales, shown in US$ billion.
| ランク | 会社 | 本部 | 2025 Rx sales (US$ billion) |
|---|---|---|---|
| 1 | イーライリリー | アメリカ合衆国 | 60.78 |
| 2 | Johnson & Johnson | アメリカ合衆国 | 59.33 |
| 3 | アッヴィ | アメリカ合衆国 | 58.27 |
| 4 | ロシュ | スイス | 57.51 |
| 5 | アストラゼネカ | 英国 | 55.04 |
| 6 | Merck & Co. (MSD) | アメリカ合衆国 | 54.69 |
| 7 | ノバルティス | スイス | 54.33 |
| 8 | ファイザー | アメリカ合衆国 | 49.91 |
| 9 | サノフィ | フランス | 48.97 |
| 10 | ブリストル・マイヤーズ スクイブ | アメリカ合衆国 | 47.75 |
| 11 | ノボ ノルディスク | デンマーク | 46.80 |
| 12 | GSK (GlaxoSmithKline) | 英国 | 42.72 |
| 13 | アムジェン | アメリカ合衆国 | 34.95 |
| 14 | 武田 | 日本 | 29.67 |
| 15 | ギリアド・サイエンシズ | アメリカ合衆国 | 28.83 |
| 16 | ベーリンガーインゲルハイム | ドイツ | 23.82 |
| 17 | バイエル | ドイツ | 19.19 |
| 18 | CSL | オーストラリア | 15.44 |
| 19 | ヴィアトリス | アメリカ合衆国 | 14.09 |
| 20 | テバ | イスラエル | 14.08 |
| 21 | アステラス製薬 | 日本 | 12.60 |
| 22 | 第一三共 | 日本 | 12.04 |
| 23 | バーテックス・ファーマシューティカルズ | アメリカ合衆国 | 11.97 |
| 24 | サンドグループ | スイス | 11.09 |
| 25 | 大塚ホールディングス | 日本 | 9.87 |
| 26 | メルクKGaA | ドイツ | 9.73 |
| 27 | UCB | ベルギー | 8.24 |
| 28 | グリフォルス | スペイン | 7.33 |
| 29 | バイオジェン | アメリカ合衆国 | 7.12 |
| 30 | サン・ファーマ | インド | 6.44 |
| 31 | リジェネロン | アメリカ合衆国 | 6.31 |
| 32 | オルガノン | アメリカ合衆国 | 6.06 |
| 33 | 雲南白養 | 中国 | 5.72 |
| 34 | アボット | アメリカ合衆国 | 5.51 |
| 35 | 奉仕者 | フランス | 5.44 |
| 36 | Bausch Health | カナダ | 5.41 |
| 37 | BeOne Medicines (formerly BeiGene) | スイス | 5.28 |
| 38 | フレゼニウス | ドイツ | 5.21 |
| 39 | Shanghai Pharmaceuticals | 中国 | 5.16 |
| 40 | エーザイ | 日本 | 4.78 |
| 41 | Sino Biopharmaceutical | 香港 | 4.37 |
| 42 | メナリニ | イタリア | 4.36 |
| 43 | インサイト | アメリカ合衆国 | 4.35 |
| 44 | イプセン | フランス | 4.16 |
| 45 | argenx | オランダ | 4.15 |
| 46 | ジャズ製薬 | アイルランド | 4.02 |
| 47 | STADA | ドイツ | 4.02 |
| 48 | 華東医学 | 中国 | 3.97 |
| 49 | 江蘇恒瑞医学 | 中国 | 3.85 |
| 50 | Haleon | 英国 | 3.60 |
Data source: Pharm Exec, 2026 Pharm Exec 50 (FY 2025 prescription drug sales). Company names use common English forms; BeOne Medicines appears under its current name (formerly BeiGene).
The headline change this year is Eli Lilly’s jump from No. 11 in the previous ranking to No. 1, with about $60.8 billion in 2025 Rx sales, up roughly 49% year over year. Johnson & Johnson, last year’s leader, is now No. 2. AbbVie, Roche, and AstraZeneca complete the top five.
Fifteen companies in the Top 50 are headquartered in the United States, still the largest national group, with particular strength in oncology, immunology, biologics, and metabolic disease, including GLP-1 therapies.
Switzerland is represented by Roche, Novartis, Sandoz, and BeOne Medicines (formerly BeiGene, now listed with a Swiss headquarters). Japan remains well represented by Takeda, Astellas, Daiichi Sankyo, Otsuka, and Eisai. Germany includes Boehringer Ingelheim, Bayer, Merck KGaA, Fresenius, and STADA.
Five Chinese companies are in this year’s list if Sino Biopharmaceutical (Hong Kong) is included: Yunnan Baiyao, Shanghai Pharmaceuticals (a new entrant), Sino Biopharmaceutical, Huadong Medicine, and Jiangsu Hengrui Medicine. CSPC Pharmaceutical Group is no longer in the Top 50. From India, Sun Pharma remains on the list; Dr. Reddy’s Laboratories is not in this year’s Top 50. New global entrants also include argenx (Netherlands) and Haleon (UK).
If you are involved in pharmaceutical machinery manufacturing, packaging solutions (vials, bottles, blister, ampoules), API and excipient supply, or contract manufacturing (CDMO/CMO), this list directly reflects where purchasing power is concentrated, which companies control global drug production, and who your most valuable long-term customers may be.
Based on this ranking, the pharmaceutical industry will continue focusing on biologics and biosimilars, GLP-1 diabetes and obesity drugs, cancer immunotherapy, rare disease treatments, and personalized medicine. Companies at the top of the 2026 Pharm Exec 50 are expected to drive mergers and acquisitions, equipment upgrades, and new plant investments worldwide.
Most companies in this ranking run large oral solid dosage (OSD) operations alongside biologics. Their tablet and capsule plants are built around a similar process chain, and each step needs GMP-grade equipment that produces repeatable batches. We cover this in detail in what equipment the global Top 50 pharma companies use to ensure quality.
| プロセスステップ | 目的 | Related JIANPAI equipment |
|---|---|---|
| 湿潤顆粒 | Densify powders and improve flow and content uniformity | 高せん断ミキサー造粒機 (JHZ-C, JHZ-D) |
| 乾燥 | Reduce granule moisture to the validated level | Fluid bed dryers (JFG-C) |
| Sizing and milling | Control particle size before blending | 製薬工場 (JZLサイジング造粒機) |
| Blending | Mix granules with lubricants and excipients | Pharma blenders (JPH 三偏心ミキサー) |
| コーティング | Film, sugar or enteric coating of tablets | 錠剤コーティング機 (国債-D, 国債-E) |
| Integrated lines | Closed, linked granulation lines that reduce manual handling | Totally enclosed granulating production line, 継続的な製造 |
Generic and contract manufacturers that supply these leaders, or compete with them, often benchmark their own lines against the same standards. For budget planning, see our 錠剤コーティング機の価格ガイド.
The 2026 Global Top 50 Pharmaceutical Companies Ranking provides a clear overview of the world’s leading drug manufacturers, based on 2025 prescription drug sales, and reflects the direction of the global pharmaceutical industry. From biologics and oncology to diabetes, obesity, and rare disease therapies, these top companies will continue to drive innovation, capacity expansion, and equipment upgrades worldwide.
製薬機械の専門メーカーとして、 JIANPAI closely follows the development trends of these global pharma leaders and is committed to providing reliable, high-efficiency production and processing solutions for pharmaceutical manufacturers across the world. Whether you are planning a new production line, upgrading existing equipment, or expanding your formulation and packaging capacity, JIANPAI offers customized solutions to meet your exact needs.
Eli Lilly is No. 1 in the 2026 Pharm Exec 50, with about $60.8 billion in 2025 prescription (Rx) drug sales. Johnson & Johnson is No. 2. The complete Top 50 table above ranks companies by 2025 Rx sales, as described in the methodology section.
Large OSD plants typically run high shear wet granulation, fluid bed drying, milling and sizing, blending, tablet compression, and film or functional coating, often with closed material transfer and automated cleaning.
Top companies set the quality and compliance expectations that generic and contract manufacturers follow. Equipment that meets their GMP, data integrity and containment needs is increasingly expected across the industry.
JIANPAI supplies granulation, drying, milling, blending and coating equipment for oral solid dosage plants. Send us your products and target capacity for a line proposal.
電子メール: [email protected] | 電話番号: +86 577-86932456 |中国浙江省温州市欧江口新区霊徳路989号